BioVersys AG
BIOV
Company Profile
Business description
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The company focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others.
Contact
c/o Technologiepark
Hochbergerstrasse 60c
BaselCH-4057
CHET: +41 615515120
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,828.70 | 2.30 | 0.03% |
| CAC 40 | 7,715.60 | 7.87 | -0.10% |
| DAX 40 | 24,084.86 | 11.19 | 0.05% |
| Dow JONES (US) | 44,406.36 | 422.17 | -0.94% |
| FTSE 100 | 8,811.61 | 5.08 | 0.06% |
| HKSE | 24,134.74 | 246.91 | 1.03% |
| NASDAQ | 20,412.52 | 188.59 | -0.92% |
| Nikkei 225 | 39,688.81 | 101.13 | 0.26% |
| NZX 50 Index | 12,859.02 | 94.07 | 0.74% |
| S&P 500 | 6,229.98 | 49.37 | -0.79% |
| S&P/ASX 200 | 8,590.70 | 1.40 | 0.02% |
| SSE Composite Index | 3,497.48 | 24.35 | 0.70% |